CA2690956C - Comprime de combinaison avec une couche exterieure pouvant etre machee - Google Patents

Comprime de combinaison avec une couche exterieure pouvant etre machee Download PDF

Info

Publication number
CA2690956C
CA2690956C CA2690956A CA2690956A CA2690956C CA 2690956 C CA2690956 C CA 2690956C CA 2690956 A CA2690956 A CA 2690956A CA 2690956 A CA2690956 A CA 2690956A CA 2690956 C CA2690956 C CA 2690956C
Authority
CA
Canada
Prior art keywords
tablet
niacin
aspirin
subject
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2690956A
Other languages
English (en)
Other versions
CA2690956A1 (fr
Inventor
Joseph Peter Habboushe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2690956A1 publication Critical patent/CA2690956A1/fr
Application granted granted Critical
Publication of CA2690956C publication Critical patent/CA2690956C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur une composition pharmaceutique sous la forme d'un comprimé de combinaison. Le comprimé comporte un composant à absorption rapide qui entre dans la circulation en traversant la muqueuse buccale, et un composant à absorption plus lente qui est avalé. L'agent thérapeutique dans la partie avalée est absorbé à travers la muqueuse gastrique. Les composants rapide et lent peuvent comporter des agents thérapeutiques identiques ou différents en fonction de l'application à un état médical spécifique. Un mode de réalisation du comprimé de combinaison comprend un inhibiteur de la prostaglandine dans le composant à absorption rapide afin d'atténuer les effets secondaires de la niacine à libération immédiate qui se trouve dans le composant à absorption lente. Ces compositions de combinaison augmenteront l'observance du patient grâce à la réduction du nombre de comprimés qu'un patient devra absorber de façon quotidienne.
CA2690956A 2007-07-01 2008-07-01 Comprime de combinaison avec une couche exterieure pouvant etre machee Active CA2690956C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94744007P 2007-07-01 2007-07-01
US60/947,440 2007-07-01
PCT/US2008/008191 WO2009005803A1 (fr) 2007-07-01 2008-07-01 Comprimé de combinaison avec une couche extérieure pouvant être mâchée

Publications (2)

Publication Number Publication Date
CA2690956A1 CA2690956A1 (fr) 2009-01-08
CA2690956C true CA2690956C (fr) 2017-01-03

Family

ID=40226425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2690956A Active CA2690956C (fr) 2007-07-01 2008-07-01 Comprime de combinaison avec une couche exterieure pouvant etre machee

Country Status (4)

Country Link
EP (1) EP2170051A1 (fr)
JP (1) JP2010532358A (fr)
CA (1) CA2690956C (fr)
WO (1) WO2009005803A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
LT2801354T (lt) 2004-10-08 2017-06-26 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8404275B2 (en) 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
WO2011009602A1 (fr) 2009-07-22 2011-01-27 Grünenthal GmbH Forme galénique extrudée à chaud à libération contrôlée
TWI473628B (zh) 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
CA2808219C (fr) 2010-09-02 2019-05-14 Gruenenthal Gmbh Forme pharmaceutique inviolable comportant un sel inorganique
WO2012028318A1 (fr) 2010-09-02 2012-03-08 Grünenthal GmbH Forme pharmaceutique inviolable comportant un polymère anionique
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
CA2853804C (fr) * 2011-10-28 2021-06-01 Vitalis Llc Compositions anti-bouffee
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
CA3042642A1 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
EP3073994A1 (fr) 2013-11-26 2016-10-05 Grünenthal GmbH Préparation de composition pharmaceutique en poudre par cryo-broyage
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3142646A1 (fr) 2014-05-12 2017-03-22 Grünenthal GmbH Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
CA2955229C (fr) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus a liberation immediate
WO2016064873A1 (fr) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2017042325A1 (fr) 2015-09-10 2017-03-16 Grünenthal GmbH Protection contre un surdosage par voie orale à l'aide de formulations à libération immédiate dissuasives d'abus
US11382873B1 (en) * 2021-01-08 2022-07-12 Vitalis Analgesics LLC Oral administration of ketamine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2076983A1 (fr) * 1990-04-11 1991-10-12 Robert Wu-Wei Shen Revetement en lit fluidise permettant de masquer le gout de l'ibuprofene
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
US6114370A (en) * 1998-09-28 2000-09-05 Wall, Jr.; William H. Amnesic sedation composition and method of administering same
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US20050045197A1 (en) * 2003-08-28 2005-03-03 Gelder Steven K. Multiple drug delivery system & method
GB0427145D0 (en) * 2004-12-10 2005-01-12 Ketocytonyx Inc Compositions for use in surgery
WO2006079021A2 (fr) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Methodes et compositions destinees au traitement des bouffees vasomotrices et de la prise de poids d'origine medicamenteuse

Also Published As

Publication number Publication date
JP2010532358A (ja) 2010-10-07
EP2170051A1 (fr) 2010-04-07
CA2690956A1 (fr) 2009-01-08
WO2009005803A1 (fr) 2009-01-08

Similar Documents

Publication Publication Date Title
CA2690956C (fr) Comprime de combinaison avec une couche exterieure pouvant etre machee
US8652520B2 (en) Combination tablet with chewable outer layer
JP6226916B2 (ja) 医薬組成物
US20250144121A1 (en) Compositions and methods for treating multiple sclerosis
US20080255104A1 (en) Nsaid Compositions
US20060134206A1 (en) Oral compositions for treatment of diseases
US20100086495A1 (en) Compositions and methods for enhancing transmucosal delivery
US20220008342A1 (en) Combination tablet with chewable outer layer
CN101198327B (zh) 治疗半夜失眠的固体组合物和方法
US7780977B2 (en) Medication compositions
US20150224056A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
US20130143912A1 (en) Sublingual zolpidem formulations
WO2012146314A1 (fr) Capsules fines de gélatine permettant la libération rapide de médicament dans la bouche
Nagpal et al. Patent innovations in fast dissolving/disintegrating dosage forms
CN104105478A (zh) 抗发红组合物
US20170246194A1 (en) Acetaminophen-Containing Analgesic Formulations With Reduced Hepatotoxicity
HK1259508B (zh) 氘代多潘立酮组合物和用於治疗病症的方法
HK1145630A (en) Compositions and methods for enhancing transmucosal delivery

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130628

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250603

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250603